Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland

2016 ◽  
Vol 40 (1) ◽  
pp. 55-62 ◽  
Author(s):  
R. Ciampi ◽  
C. Romei ◽  
L. Pieruzzi ◽  
A. Tacito ◽  
E. Molinaro ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Point Mutations ◽  
Medullary Thyroid ◽  
Ras Oncogenes ◽  
Classical Point

scholarly journals Indication and Timing of Thyroid Surgery for Patients with Hereditary Medullary Thyroid Cancer Syndromes

2006 ◽  
Vol 4 (2) ◽  
pp. 139-147 ◽  
Author(s):  
Jennifer B. Ogilvie ◽  
Electron Kebebew
Keyword(s):  
Thyroid Cancer ◽  
Multiple Endocrine Neoplasia ◽  
Medullary Thyroid Cancer ◽  
Autosomal Dominant ◽  
Point Mutations ◽  
Prophylactic Thyroidectomy ◽  
Medullary Thyroid ◽  
Hereditary Medullary Thyroid Cancer ◽  
Cancer Syndromes

Hereditary medullary thyroid cancer syndromes comprise familial medullary thyroid cancer (FMTC) and multiple endocrine neoplasia types 2A and 2B. Hereditary medullary thyroid cancers have an autosomal dominant pattern of inheritance and are caused by activating germline point mutations in the RET proto-oncogene. Evaluation of the onset, extent, and progression of hereditary medullary thyroid cancer associated with specific RET mutations has enabled clinicians to treat patients based on the level of risk associated with their specific mutation. Children identified by RET screening to be at risk for the development of medullary thyroid cancer can be treated with prophylactic thyroidectomy before developing the disease. This review covers the diagnosis, evaluation, timing of surgical management, and optimal follow-up of patients with hereditary medullary thyroid cancer syndromes.

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

NTRK3 receptor expression is strictly associated with medullary thyroid cancer RET mutation status

2014 ◽  
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Michal Swierniak ◽  
Malgorzata Kowalska ◽  
Agnieszka Pawlaczek ◽  
Monika Kowal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Receptor Expression ◽  
Mutation Status ◽  
Medullary Thyroid ◽  
Ret Mutation

Clinical usefulness of dynamic risk stratification in medullary thyroid cancer

2016 ◽  
Author(s):  
Ji Min Han ◽  
Hyemi Kwon ◽  
Won Gu Kim ◽  
Min Ji Jeon ◽  
Tae Yong Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Medullary Thyroid Cancer ◽  
Clinical Usefulness ◽  
Medullary Thyroid ◽  
Dynamic Risk

Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

2019 ◽  
Author(s):  
George Simeakis ◽  
Katerina Saltiki ◽  
Evangelia Zapanti ◽  
Evanthia Kassis ◽  
Maria Alevizaki
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Medullary Thyroid
Sign in / Sign up

Export Citation Format

Share Document